FDA demands new warnings on dermal fillers from Actavis, Galderma

Carly Helfand Dermal fillers are meant to minimize the appearance of wrinkles and give the face a smoother, fuller appearance. But they may also have some nasty consequences if injected ...

Suicide stunner prompts Amgen to dump brodalumab for psoriasis, walk away from AstraZeneca

John Carroll FierceBiotech News

Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costs

Eric Palmer Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor. FiercePharma News

UPDATED: Endo aims to lure Salix from Valeant with $175-per-share offer

Carly Helfand Last month, some industry watchers speculated that the low price Valeant agreed to pay for North Carolina's Salix could leave room for other bids. And now, one has ...

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

Carly Helfand So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going. FiercePharma News

Canadian paper backpedals from Gardasil side effects story

Carly Helfand Merck has already had its fair share of struggles with uptake rates for its HPV vaccine, Gardasil. A Toronto Star story from earlier this month, which focused on young ...

Bayer feels sting of mixed decision from NICE for Eylea’s use in diabetics

Emily Wasserman Bayer has won an approval from England's National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The ...

Can Actavis deliver a promised $6B boost from this pipeline?

John Carroll FierceBiotech News

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets

EJ Lane FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth quarter earnings calls to explain what C-suite executives are ...

Struggling Lilly, AbbVie may find Low-T boost from specialized testosterone clinics

Carly Helfand After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their ...

Esperion gets out from under the FDA and speeds toward Phase III

Damian Garde Ann Arbor, MI, biotech Esperion Therapeutics finally resolved the FDA snag standing in the way of its ambitious plans for a new cholesterol drug, clearing the company to ...

Trans-Pacific Partnership push waits on cue from Obama’s India visit

EJ Lane SINGAPORE–India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS